29 Mar, 2024 ABA Antitrust Law Spring Meeting By Axinn Insights Axinn is proud to be participating in the 72nd ABA Antitrust Law Spring Meeting and other adjacent events. The Spring Meeting is the...
29 Mar, 2024 ChromaDex Stands Out, But Not in a Good Way By Ted Mathias The law of patent eligibility was pretty quiet for decades until the Supreme Court breathed new life into Section 101 invalidity...
28 Mar, 2024 The Rise of Labor Issues as an Antitrust Priority By Rick Dagen Maryanne Magnier and I have drafted an article titled, “The Rise of Labor Issues as an Antitrust Priority.” The article will soon appear...
27 Mar, 2024 Puma and the Pitfalls of the “Narrow” Exclusive License By Ted Mathias Matt Murphy Puma Biotechnology is the latest victim of standing requirements in patent cases that continue to wreak havoc on plaintiffs’ ability to...
25 Mar, 2024 The Surprising Power of the Connecticut PJR By Nicholas Duffee Jarod Taylor A recent decision reported by Law360 is a useful reminder of the power of a remedy peculiar to Connecticut courts, the prejudgment remedy...
25 Mar, 2024 More Lessons from Mumbai – Reflections on a Hatch-Waxman and PIV Litigation Panel Discussion By Chad Landmon Reflecting back on our time at the 13th Annual Pharma IPR Conference in Mumbai, there was a lively discussion during the panel that I...
22 Mar, 2024 CEMCO Can't Get What It Wants, But Probably What It Needs By Ted Mathias Earlier this month, I previewed a Federal Circuit oral argument in In re: California Expanded Metal Products Co., No. 2023-1140, where...
20 Mar, 2024 European Commission Merger Policy Speech Reflects Alignment with US Agency Policy, Pre-2021 By Mike Keeley Today's speech by Guillaume Loriot -- the EC's Deputy Director General for Mergers -- is worth a read. Without agreeing necessarily with...
20 Mar, 2024 USITC Commissioner Series: the Era of the Mini-Opinion Has Begun By Brian Johnson This is part one of our USITC Commissioner Series. Read part two here, part three here, part four here and part five here. At the...
18 Mar, 2024 Going Global on Polymorphs By Ted Mathias Aziz Burgy Rebecca Clegg We were so pleased to have the opportunity to address InformaMarkets’ 13th Annual Pharma IPR Conference in Mumbai on legal challenges to...
14 Mar, 2024 Done Shopping By Jeannine Sano On March 12, 2024, the Judicial Conference of the United States announced an amendment of the policy governing random case assignment to...
12 Mar, 2024 Artificial Intelligence and Pricing Algorithms in the Antitrust Spotlight By Axinn Insights As we navigate the ever-evolving terrain of technology and market dynamics, it’s vital to stay ahead with insights that transcend the...
11 Mar, 2024 Axinn at the 2024 ABA White Collar Crime Conference By Dan Oakes The 2024 ABA White Collar Crime Conference in San Francisco was filled with insightful discussion on hot topics in recent U.S. criminal...
11 Mar, 2024 Reconnecting in Mumbai at the 2024 Pharma IPR Conference By Chad Landmon Aziz Burgy Ted Mathias Rebecca Clegg +1 more... Show less We just returned from a weeklong trip to Mumbai in which Axinn served as the Platinum sponsor of InformaMarkets 13th Annual Pharma IPR...
07 Mar, 2024 The Power of the Purse Hits DOJ's Antitrust Division By Mike Keeley In almost every way, the party of the U.S. President controls federal antitrust enforcement policy. The one exception is control over...
06 Mar, 2024 Indefinite Contradiction or Inartful Claim Narrowing? By Chantelle Ankerman Earlier today the Federal Circuit in Maxell v. Amperex, No. 23-1194, vacated a District Court’s indefiniteness determination after...